GEPI20105143B - Combination of azelastine and fluticasone - Google Patents

Combination of azelastine and fluticasone

Info

Publication number
GEPI20105143B
GEPI20105143B GEAP201011799A GEAP2010011799A GEPI20105143B GE PI20105143 B GEPI20105143 B GE PI20105143B GE AP201011799 A GEAP201011799 A GE AP201011799A GE AP2010011799 A GEAP2010011799 A GE AP2010011799A GE PI20105143 B GEPI20105143 B GE PI20105143B
Authority
GE
Georgia
Prior art keywords
azelastine
fluticasone
combination
solvate
compound
Prior art date
Application number
GEAP201011799A
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Sipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GB0213739A priority Critical patent/GB2389530B/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9938620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEPI20105143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sipla Ltd filed Critical Sipla Ltd
Publication of GEPI20105143B publication Critical patent/GEPI20105143B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions

Abstract

A pharmaceutical product or compound which contains azelastine or pharmaceutically acceptable salt thereof, solvate or physiologically functioning derivative and steroid, or pharmaceutically acceptable salt, solvate or physiologically functioning derivatives, wherein the product or its compound are presented in nasal or ocular designation in the appropriate forms.
GEAP201011799A 2002-06-14 2010-07-12 Combination of azelastine and fluticasone GEPI20105143B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0213739A GB2389530B (en) 2002-06-14 2002-06-14 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GEPI20105143B true GEPI20105143B (en) 2011-01-25

Family

ID=9938620

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201011799A GEPI20105143B (en) 2002-06-14 2010-07-12 Combination of azelastine and fluticasone

Country Status (29)

Country Link
US (10) US8168620B2 (en)
EP (3) EP2072051B1 (en)
KR (3) KR101119895B1 (en)
CN (1) CN1674910A (en)
AP (1) AP200403192A0 (en)
AT (1) AT428428T (en)
AU (3) AU2003244799B2 (en)
BR (2) BRPI0312128B1 (en)
CA (3) CA2489427C (en)
CR (1) CR7654A (en)
CY (3) CY1109196T1 (en)
DE (1) DE60327203D1 (en)
DK (3) DK2072051T3 (en)
ES (3) ES2324910T3 (en)
GB (1) GB2389530B (en)
GE (1) GEPI20105143B (en)
HU (2) HUE027184T2 (en)
IL (3) IL165771A (en)
LU (1) LU92269I2 (en)
MA (1) MA27285A1 (en)
MX (1) MXPA04012666A (en)
NZ (2) NZ574658A (en)
PL (1) PL373001A1 (en)
PT (3) PT2072051E (en)
RU (1) RU2361593C2 (en)
SI (3) SI2072051T1 (en)
TN (1) TNSN04247A1 (en)
WO (1) WO2003105856A1 (en)
ZA (1) ZA200500331B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003273396B2 (en) * 2002-08-30 2008-12-11 Covis Pharma B.V. The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
RS58377B1 (en) * 2004-11-24 2019-04-30 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
KR20070121786A (en) 2005-03-23 2007-12-27 엘란 파마 인터내셔널 리미티드 Nanoparticulate corticosteroid and antihistamine formulations
AR059358A1 (en) * 2006-02-09 2008-03-26 Schering Corp pharmaceutical formulations
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. nasal administration of aqueous solutions of corticosteroids
DE102006034883A1 (en) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Composition, useful to treat inflammatory skin disease, e.g. psoriasis, comprises mometasone furoate, water, a combination of aromatic alcohol and a solvent e.g. alkoxylated fatty-alcohol and/or aliphatic alcohol, and further additives
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US9254286B2 (en) 2009-03-17 2016-02-09 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
CA2764473A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2011035513A1 (en) 2009-09-28 2011-03-31 Cao Hongguang X-ray image detection device
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
KR101261230B1 (en) 2010-11-29 2013-05-07 한림제약(주) Mometasone furoate, and a pharmaceutical composition for intranasal administration containing azelastine hydrochloride
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
US20140219949A1 (en) * 2011-06-22 2014-08-07 Jiangsu Deda Pharmaceuticals Co. Ltd Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
KR101304341B1 (en) * 2011-09-19 2013-09-11 한미약품 주식회사 PHARMACEUTICAL COMPOSITION COMPRISING CORTICOSTEROID, ANTIHISTAMINIC AGENT AND β-CYCLODEXTRIN WITH IMPROVED STABILITY
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201121812D0 (en) * 2011-12-07 2012-02-01 Teva Branded Pharmaceutical Prod R & D Inc NAsal formulation
CN104159635B (en) * 2012-02-27 2018-09-25 奥雷制药有限公司 For delivering a therapeutic agent in the treatment of otic disorders cochlea to solid pharmaceutical implant
WO2014087347A1 (en) * 2012-12-06 2014-06-12 Glenmark Pharmaceuticals Limited Fixed dose pharmaceutical composition comprising mometasone and azelastine
KR20140081925A (en) * 2012-12-12 2014-07-02 한미약품 주식회사 Taste masked pharmaceutical formulation comprising corticosteroid, antihistamine and stevia
JP2016513662A (en) 2013-03-13 2016-05-16 フラットリー ディスカバリー ラブ Methods for the treatment of pyridazinone compounds and cystic fibrosis
CN103784462A (en) * 2014-02-25 2014-05-14 宋俊智 Pharmaceutical preparation containing bilastine and steroids
EP2985019A1 (en) * 2014-08-16 2016-02-17 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
CN104173286B (en) * 2014-09-10 2017-03-01 贵州云峰药业有限公司 Azelastine compositions and uses
WO2017201003A1 (en) * 2016-05-17 2017-11-23 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1059906B (en) 1954-10-05 1959-06-25 Scherico Ltd A process for the preparation of 1, 4-Pregnadienen
US2837464A (en) 1955-01-11 1958-06-03 Schering Corp Process for production of dienes by corynebacteria
US3067197A (en) 1961-04-26 1962-12-04 Pfizer & Co C 11-oxygenated 6alpha-fluoro-16-methylene-delta-pregnenes and derivatives
FR4548M (en) 1963-06-11
GB1159490A (en) 1966-02-09 1969-07-23 Boots Pure Drug Co Ltd Improvements in Acylated Steroids
US3639434A (en) 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
IT1061787B (en) 1967-03-01 1983-04-30 Vismara Francesco Spa Improvements relating to the preparation of 17 benzoate betametazone
GB1227992A (en) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
IT1034011B (en) 1969-06-26 1979-09-10 Vister Vismara Terapeutici S P Process for the prapratzione 17 monoesters of 17 to 21 diossisteroidi by hydrolysis die corpispondenti 17 21 cyclic orthoesters ph control side
GB1384372A (en) 1971-01-20 1975-02-19 Glaxo Lab Ltd Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids
CH572914A5 (en) 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US3828080A (en) 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US3989686A (en) 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
GB1438940A (en) 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
GB1440063A (en) 1972-08-11 1976-06-23 Glaxo Lab Ltd 17alpha-esters of 17alpha,21-dihydroxy-20-oxo-steroids
GB1517278A (en) 1974-08-30 1978-07-12 Glaxo Lab Ltd Alkyl and haloalkyl androsta-1,4,15-triene and-4,15-diene-17beta-carboxylates
US4093721A (en) 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
YU54476A (en) 1975-03-31 1982-05-31 Taisho Pharma Co Ltd Process for obtaining 17-ester 21-halo-pregnane
CH628355A5 (en) 1976-02-24 1982-02-26 Ciba Geigy Ag Method for manufacturing new androstadien-17beta-carboxylic acids and their esters and salts.
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4198403A (en) 1978-04-05 1980-04-15 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
US4263289A (en) 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4188385A (en) 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives
US4261984A (en) 1978-04-05 1981-04-14 Syntex (U.S.A.) Inc. 17β-thiocarboxylic acid esters of 3-oxo-4-halo-16β-methylandrost-4-enes
US4310466A (en) 1979-08-31 1982-01-12 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
DE2817988A1 (en) 1978-04-25 1979-11-08 Hoechst Ag Corticoid 17-alkyl carbonates and methods for their preparation
US4267173A (en) 1979-11-05 1981-05-12 Schering Corporation Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
BE887518A (en) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates of norandrostanes
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
ZA8104440B (en) 1980-07-10 1982-10-27 Otsuka Pharma Co Ltd Soft steroids having anti-inflammatory activity
SE449106B (en) 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid anti-inflammatory action and composition CONTAINING this
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
AT8790T (en) 1981-02-02 1984-08-15 Schering Corporation Aromatic heterocyclic steroidester, processes for their preparation and pharmaceutical compositions containing them.
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4607028A (en) 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US4552899B1 (en) 1984-04-09 1992-10-20 Analgesic Associates
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co., Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4861765A (en) 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
WO1989003390A1 (en) 1987-10-13 1989-04-20 Bodor Nicholas S Soft steroids having anti-inflammatory activity
US5232919A (en) 1987-11-13 1993-08-03 Asta Pharma Aktiengesellschaft Azelastine embonate and compositions which contain it
DE3836579A1 (en) 1987-11-13 1989-05-24 Asta Pharma Ag Azelastine-containing pharmaceutical compositions for use in the nose and/or on the eye
EP0316633B1 (en) 1987-11-13 1993-01-27 ASTA Medica Aktiengesellschaft Medicine containing azelastine for application in the nose and/or at the eye
US5271946A (en) 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5202316A (en) 1989-03-22 1993-04-13 Roussel Uclaf N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines
FR2644788B1 (en) 1989-03-22 1995-02-03 Roussel Uclaf 3-keto new steroids having a chain 17 amino-substituted, their method of preparing and intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them
JPH07116215B2 (en) 1989-04-19 1995-12-13 エスエス製薬株式会社 The novel steroid compound
AT107643T (en) * 1989-05-05 1994-07-15 Asta Medica Ag Salts of azelastine with improved solubility.
JPH04506066A (en) 1989-06-16 1992-10-22
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Pharmaceutical compositions comprising salmeterol and fluticasone propionate
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of Thienylcarbonsäuren with aminoalcohols, their quaternization products, processes for their preparation and pharmaceutical compositions containing them
DE4025342A1 (en) 1990-08-10 1992-02-13 Hoechst Ag In position 17 substituted corticoid-17-alkylcarbonates, processes for their preparation and pharmaceutical compositions containing them
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
JP3087763B2 (en) 1990-11-30 2000-09-11 三井化学株式会社 The novel heterocyclic compounds and pharmaceutical compositions containing them
GB9103764D0 (en) 1991-02-22 1991-04-10 Glaxo Group Ltd Compositions
DE69231991D1 (en) * 1991-06-10 2001-09-13 Schering Corp Chlorofluorocarbons Hydrogen-free aerosol formulations
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
JPH08502288A (en) 1992-10-09 1996-03-12 ザ、プロクター、エンド、ギャンブル、カンパニー Pharmaceutical compositions and usage for treating KanAkira symptoms
NO941358L (en) 1993-04-16 1994-10-17 Mcneil Ppc Inc Aqueous pharmaceutical suspension and methods of preparation thereof
DE4322703A1 (en) 1993-07-08 1995-01-12 Asta Medica Ag Aerosols using polyoxyethylene glyceryl fettsäureestern as suspension stabilizers and valve lubricants
JP4208267B2 (en) 1993-07-30 2009-01-14 キヤノン株式会社 Control device
DE4328819A1 (en) 1993-08-27 1995-03-02 Hoechst Ag Corticosteroid 17-alkyl-21/0 / -carboxylic acid and carbonate ester, process for their preparation and pharmaceutical compositions containing them
DE4333920A1 (en) 1993-10-05 1995-04-13 Hoechst Ag Corticoid 17,21-dicarboxylic acid esters and corticosteroid-17-carbonsäureester-21-carbonate ester, process for their preparation and pharmaceutical compositions containing them
WO1995013810A1 (en) 1993-11-19 1995-05-26 Schering-Plough Healthcare Products Incorporated Nasal spray compositions containing oxymetazoline
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
IL109656A (en) 1994-05-15 1998-02-22 Chemagis Ltd Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
GB9419536D0 (en) 1994-09-28 1994-11-16 Glaxo Inc Medicaments
AR002009A1 (en) 1994-12-22 1998-01-07 Astra Ab pharmaceutical composition, process for the manufacture of a proliposome powder as used in said composition, process for lamanufactura of said composition, use of said pharmaceutical composition in the manufacture of a medicament and dry powder inhaler device.
DE4446891A1 (en) 1994-12-27 1996-07-04 Falk Pharma Gmbh A stable aqueous budesonide solution
DE69636757T2 (en) 1995-04-14 2007-10-11 Smithkline Beecham Corp. Metered dose inhaler for Fluticasonepropionat
JPH08291072A (en) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd Crystal for inhaling powder preparation and its production
JPH08291073A (en) 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd Medicinal composition and its production
AU6392496A (en) * 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
DE19528145A1 (en) 1995-08-01 1997-02-06 Boehringer Ingelheim Kg New drugs and their use
GB9521696D0 (en) 1995-10-23 1996-01-03 Bayer Ag Combination of LTD4 receptor antagonists with glucocorticosteriods
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
US5707984A (en) 1995-12-08 1998-01-13 G. D. Searle & Co. Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs
EP0780127A1 (en) * 1995-12-19 1997-06-25 THE PROCTER & GAMBLE COMPANY A nasal spray containing a steroid and a antihistamine
CA2241728A1 (en) 1995-12-29 1997-07-10 Panayiotis Alexandrou Procopiou Lactone derivatives of 17.beta.-carboxy, carbothio and amide androstane derivatives
ES2205177T5 (en) 1996-02-27 2007-08-01 Teijin Limited Powder composition for nasal administration.
US5985862A (en) 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US5981517A (en) 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
JPH11511758A (en) 1996-06-04 1999-10-12 ザ、プロクター、エンド、ギャンブル、カンパニー Nasal sprays, including nasal steroids and antihistamines
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
FR2756739B1 (en) 1996-12-05 2000-04-28 Astra Ab New formulation of budesonide
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5830490A (en) 1997-04-04 1998-11-03 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders
BR9809022A (en) * 1997-04-30 2000-08-01 Warner Lambert Co anti-inflammatory topical nasal compositions
JP2000513380A (en) 1997-06-30 2000-10-10 グラクソ、グループ、リミテッド Compound
EP0903151A1 (en) 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5972327A (en) 1997-10-22 1999-10-26 Lin; Matthew M. Method of treating allergic rhinitis by delivering medication via the nasal vestibules
SE9704186D0 (en) 1997-11-14 1997-11-14 Astra Ab New composition of matter
SE9704833D0 (en) 1997-12-22 1997-12-22 Astra Ab New formulation
US5972920A (en) 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
FR2779841B1 (en) 1998-06-15 2006-08-04 Peugeot Method and device for controlling an electric actuator activating a functional system
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6136294C1 (en) 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
SE9803770D0 (en) 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
US6261539B1 (en) 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6294153B1 (en) * 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
EP1020233A1 (en) 1999-01-13 2000-07-19 THE PROCTER & GAMBLE COMPANY Dosing and delivering system
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
GEP20053474B (en) 1999-04-30 2005-03-25 Pfizer Prod Inc Glucocorticoid Receptor Modulators
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa New quinuclidine derivatives and pharmaceutical compositions containing them.
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
AU7703400A (en) 1999-09-14 2001-04-17 Xenoport, Inc. Substrates and screening methods for transport proteins
DE19947234A1 (en) * 1999-09-30 2001-04-05 Asta Medica Ag New combination of loteprednol and antihistamines
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
MXPA02007252A (en) 2000-01-28 2003-01-29 Rohm & Haas Enhanced propertied pharmaceuticals.
US6565832B1 (en) 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
EE200200426A (en) 2000-01-31 2003-12-15 Pfizer Products Inc. Useful as inhibitors of PDE4 isozymes pyrimidinecarboxamide
DE10007203A1 (en) 2000-02-17 2001-08-23 Asta Medica Ag Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist
US20020133032A1 (en) 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
GB0009592D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009606D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0017988D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Novel process
AU7789101A (en) 2000-07-26 2002-02-05 Alcon Universal Ltd Pharmaceutical suspension compositions lacking a polymeric suspending agent
WO2002011711A2 (en) 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
OA12394A (en) 2000-08-05 2004-07-09 Glaxo Group Ltd 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent.
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
JP2002053485A (en) 2000-08-08 2002-02-19 Oshida Tetsuo Pharmaceutical composition for allergic disease
AR032362A1 (en) 2000-08-14 2003-11-05 Glaxo Group Ltd Topical Formulation stable emulsion oil in water and process for preparation
CZ20031194A3 (en) 2000-09-29 2003-08-13 Glaxo Group Limited Urea derivatives
ZA200108461B (en) 2000-10-27 2002-06-06 Celanese Chem Europe Gmbh Process of telomerizing conjugated dienes.
WO2002036106A2 (en) 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicament compositions based on anticholinergics and corticosteroids
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
ME00242B (en) 2000-10-31 2011-05-10 Boehringer Ingelheim Pharma Inhalative solution formulation containing a tiotropium salt
US7214672B2 (en) 2000-12-22 2007-05-08 Nippon Shinyaku Co., Ltd. Preventives/remedies for inflammatory airway diseases
US20020132803A1 (en) 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US6583180B2 (en) * 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
GB0105560D0 (en) 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
AT381537T (en) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilide-derivative as beta2-adrenergic agonists
GB0108800D0 (en) 2001-04-07 2001-05-30 Glaxo Group Ltd Novel compounds
JP2005523268A (en) 2002-02-04 2005-08-04 グラクソ グループ リミテッドGlaxo Group Limited Formulations for inhalation containing glucocorticoids and β2- adrenoreceptor agonist
US20050070487A1 (en) 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
WO2002100879A1 (en) 2001-06-12 2002-12-19 Glaxo Group Limited Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
DE10130371A1 (en) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003013427A2 (en) 2001-08-03 2003-02-20 Smithkline Beecham Corporation A method for preparing fluticasone derivatives
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
CN1613012A (en) 2001-11-05 2005-05-04 布赖汉姆妇女医院 Soluble cd40l (cd154) as a prognostic marker of atherosclerotic diseases
GB0127160D0 (en) 2001-11-12 2002-01-02 Glaxo Group Ltd Novel compounds
WO2003042229A1 (en) 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
WO2003049770A1 (en) 2001-12-05 2003-06-19 Alcon, Inc. Use of an h1 antagonist and a safe steroid to treat rhinitis
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0202635D0 (en) 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
DE10216429A1 (en) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Synergistic medicaments for treating inflammatory or obstructive respiratory tract diseases, containing quaternized scopine ester anticholinergic agent and steroid, e.g. budesonide
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP3691459B2 (en) 2002-06-14 2005-09-07 久光メディカル株式会社 Powdery inhalation composition
GB0217504D0 (en) 2002-07-29 2002-09-04 Novartis Ag Organic compounds
US7244742B2 (en) 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
AU2003273396B2 (en) * 2002-08-30 2008-12-11 Covis Pharma B.V. The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US20040235807A1 (en) 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005030331A1 (en) 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2007061454A1 (en) 2005-11-22 2007-05-31 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
RS58377B1 (en) 2004-11-24 2019-04-30 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
GB0507165D0 (en) 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
AU2009302362A1 (en) * 2008-10-10 2010-04-15 Merck Sharp & Dohme Corp. Corticosteroid compositions for use in treating diseases of the upper and lower airway passages

Also Published As

Publication number Publication date
CY1116693T1 (en) 2017-03-15
CA2489427C (en) 2012-09-25
DK1519731T3 (en) 2009-08-03
US8168620B2 (en) 2012-05-01
EP2075000A1 (en) 2009-07-01
IL216932A (en) 2014-09-30
SI2072051T1 (en) 2014-07-31
PT2075000E (en) 2015-11-03
CY1115386T1 (en) 2017-01-04
US20150072010A1 (en) 2015-03-12
US20130029951A1 (en) 2013-01-31
EP1519731A1 (en) 2005-04-06
KR101301558B1 (en) 2013-09-04
US20130029952A1 (en) 2013-01-31
RU2361593C2 (en) 2009-07-20
BR0312128A (en) 2005-04-05
GB2389530B (en) 2007-01-10
US20170035780A1 (en) 2017-02-09
ES2456822T3 (en) 2014-04-23
AU2009243420A1 (en) 2009-12-24
KR101119895B1 (en) 2012-02-22
KR101301061B1 (en) 2013-08-28
US8933060B2 (en) 2015-01-13
US9259428B2 (en) 2016-02-16
AU2009243420B2 (en) 2012-10-11
CA2779630A1 (en) 2003-12-24
AU2009243422B2 (en) 2012-03-29
US20150224116A1 (en) 2015-08-13
CN1674910A (en) 2005-09-28
EP2072051B1 (en) 2014-01-29
US20090318397A1 (en) 2009-12-24
BRPI0312128B1 (en) 2018-01-30
AP200403192A0 (en) 2004-12-31
ES2545205T3 (en) 2015-09-09
US8304405B2 (en) 2012-11-06
PL373001A1 (en) 2005-08-08
HUE027184T2 (en) 2016-08-29
CA2779633C (en) 2015-11-03
DK2072051T3 (en) 2014-04-14
NZ574658A (en) 2010-09-30
SI1519731T1 (en) 2009-10-31
RU2005100781A (en) 2005-08-10
NZ537246A (en) 2007-09-28
HUS1300032I1 (en) 2017-10-30
US20100331289A1 (en) 2010-12-30
PT1519731E (en) 2009-07-13
IL165771A (en) 2014-06-30
AT428428T (en) 2009-05-15
IL165771D0 (en) 2006-01-15
ZA200500331B (en) 2006-07-26
DE60327203D1 (en) 2009-05-28
DK2075000T3 (en) 2015-09-14
GB2389530A (en) 2003-12-17
EP2072051A1 (en) 2009-06-24
ES2324910T3 (en) 2009-08-19
US20090291143A1 (en) 2009-11-26
IL216931D0 (en) 2012-01-31
AU2009243422C1 (en) 2014-01-09
KR20110113781A (en) 2011-10-18
GB0213739D0 (en) 2002-07-24
EP2075000B1 (en) 2015-07-22
PT2072051E (en) 2014-04-07
IL216932D0 (en) 2012-01-31
US20150190405A1 (en) 2015-07-09
US20060025391A1 (en) 2006-02-02
KR20110113782A (en) 2011-10-18
KR20050024362A (en) 2005-03-10
MXPA04012666A (en) 2005-09-30
US8937057B2 (en) 2015-01-20
AU2009243422A1 (en) 2009-12-17
US8318709B2 (en) 2012-11-27
CA2489427A1 (en) 2003-12-24
IL216931A (en) 2015-11-30
AU2003244799B2 (en) 2009-09-10
AU2003244799A1 (en) 2003-12-31
CY1109196T1 (en) 2014-07-02
EP1519731B1 (en) 2009-04-15
CA2779630C (en) 2014-01-28
US9901585B2 (en) 2018-02-27
CA2779633A1 (en) 2003-12-24
US8163723B2 (en) 2012-04-24
MA27285A1 (en) 2005-04-01
SI2075000T1 (en) 2015-10-30
CR7654A (en) 2007-10-22
WO2003105856A1 (en) 2003-12-24
TNSN04247A1 (en) 2007-03-12
LU92269I2 (en) 2013-10-22

Similar Documents

Publication Publication Date Title
ZA200503365B (en) Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
IL164209D0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL166620A (en) Pyrazole derivatives and pharmaceutical compositions containing the same
AR022636A1 (en) Derivatives of 16-halo-epothilone, processes for preparing them and pharmaceutical use thereof
WO2003064431A3 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
IL174952A (en) Sulfoximine-substituted pyrimidine derivatives, intermediates for their preparation and their use in the manufacture of pharmaceutical agents for treating various diseases
AU2003205315A1 (en) Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
SI1656346T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
WO2004021968A3 (en) Solution for ungual application
EP2377557A3 (en) Compositions comprising azelastine and methods of use thereof
PL213669B1 (en) Derivative of 2-oxo-1-pyrrolidyne, pharmaceutical agent and the use of this derivative
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
AU2002362612A1 (en) Prevention and treatment of restenosis by local administration of drug
EP1477482A4 (en) Novel phenylalanine derivative
AU2003242544A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
PL369671A1 (en) Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
HRP20040824A2 (en) Aminoindazole derivatives, preparation method thereof and use of intermediates of said method as medicaments and pharmaceutical compositions containing same
IL163691A (en) 5-phenylthiazole derivatives, process for their preparation, compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by pi3 kinase
CA2459311A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
IL172334A (en) Benzazepine derivatives, pharmaceutical compositions comprising them, method for producing the pharmaceutical compositions and use of said derivatives for the manufacture of medicaments
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
WO2000003997A1 (en) Thiobenzimidazole derivatives